A5091636031- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Ion channel regulation and function
- Radiomics and Machine Learning in Medical Imaging
- Neuroscience and Neuropharmacology Research
- Epilepsy research and treatment
- Medical Imaging and Pathology Studies
- Glycosylation and Glycoproteins Research
Vrije Universiteit Amsterdam
2020-2023
Amsterdam UMC Location Vrije Universiteit Amsterdam
2016-2023
Geneeskundige en Gezondheidsdienst
2023
Amsterdam University Medical Centers
2020-2022
Amsterdam Neuroscience
2016
Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or mimetics with radiometals is a prerequisite for immuno-PET. While preferably fast, mild, efficient, reproducible, especially when applied human use in current Good Manufacturing Practice compliant way, it crucial that the obtained radioimmunoconjugate shows preserved immunoreactivity vivo behavior. Radiometals chelators have extensively been evaluated to come most ideal radiometal-chelator pair each type...
Abstract Purpose Almost all radiolabellings of antibodies with 89 Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake in bones due instability resulting metal complex. DFO*-NCS and squaramide ester DFO, DFOSq, are novel analogues that gave more stable complexes than pilot experiments. Here, we directly compare these linker-chelator systems identify optimal immuno-PET reagents. Methods Cetuximab, trastuzumab B12 (non-binding control...
Probody ® therapeutics are recombinant masked monoclonal antibody (mAb) prodrugs that become activated by proteases present in the tumor microenvironment.This makes them attractive for use as drug conjugates (PDCs).CX-2009 is a novel PDC with toxic DM4 coupled to an anti-CD166 therapeutic.CD166 overexpressed multiple types and lesser extent healthy tissue.Methods: The targeting potential of CX-2009 was assessed performing 89 Zr-immuno-PET/biodistribution/therapy studies CD166-positive H292...
The recent advances in the production of engineered antibodies have facilitated development and application tailored, target-specific antibodies. Positron emission tomography (PET) these antibody-based drug candidates can help to better understand their vivo behavior. In this study, we report an proof-of-concept pretargeted immuno-PET study where compare a pretargeting vs targeted approach using new 89Zr-labeled tetrazine as bio-orthogonal ligand inverse electron demand Diels–Alder (IEDDA)...
Abstract Introduction The assessment of ex vivo biodistribution is the preferred method for quantification radiotracers in preclinical models, but not line with current ethics on animal research. PET imaging allows noninvasive longitudinal evaluation tracer distribution same animals, systemic comparison lacking. Our aim was to evaluate potential accurate quantification, especially tumor models. Methods NEMA NU 4-2008 phantoms were filled 11 C, 68 Ga, 18 F, or 89 Zr solutions and scanned...